Argus Increases Sanofi (NASDAQ:SNY) Price Target to $60.00

Sanofi (NASDAQ:SNY) had its target price boosted by Argus from $55.00 to $60.00 in a research report sent to investors on Friday morning, Marketbeat.com reports. The firm currently has a buy rating on the stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $52.09 on Friday. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.72. The business’s fifty day moving average is $49.29 and its 200 day moving average is $48.66. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $131.93 billion, a price-to-earnings ratio of 26.18, a PEG ratio of 1.63 and a beta of 0.59.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.95 earnings per share. Research analysts predict that Sanofi will post 4.14 EPS for the current year.

Institutional Investors Weigh In On Sanofi

Institutional investors and hedge funds have recently made changes to their positions in the business. POM Investment Strategies LLC purchased a new position in Sanofi during the second quarter worth about $25,000. Venturi Wealth Management LLC grew its holdings in shares of Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after purchasing an additional 332 shares in the last quarter. Frazier Financial Advisors LLC bought a new position in shares of Sanofi in the fourth quarter worth approximately $28,000. Larson Financial Group LLC raised its stake in Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after purchasing an additional 500 shares in the last quarter. Finally, Register Financial Advisors LLC bought a new stake in Sanofi during the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.